Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Shares Outstanding (Weighted Average) (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Shares Outstanding (Weighted Average) for 8 consecutive years, with $69.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 27.01% year-over-year to $69.3 million, compared with a TTM value of $69.3 million through Sep 2025, up 27.01%, and an annual FY2024 reading of $58.2 million, up 63.54% over the prior year.
  • Shares Outstanding (Weighted Average) was $69.3 million for Q3 2025 at Bicycle Therapeutics, roughly flat from $69.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $69.3 million in Q3 2025 and bottomed at $22.1 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $40.0 million, with a median of $30.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 1.34% in 2023, then surged 63.54% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $25.1 million in 2021, then increased by 18.35% to $29.7 million in 2022, then grew by 20.0% to $35.6 million in 2023, then soared by 63.54% to $58.2 million in 2024, then grew by 19.06% to $69.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BCYC at $69.3 million in Q3 2025, $69.2 million in Q2 2025, and $69.2 million in Q1 2025.